Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. INDIA PRESS-CCI issues show-cause notices to Sun Pharma, Ranbaxy - Mint

    Headlines

    Tue, 29 Jul 2014

    Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

  2. UPDATE 1-India's Ranbaxy posts loss on provision for US settlement

    Headlines

    Tue, 29 Jul 2014

    * Loss of 1.86 bln rupees due to one-off 2.4 bln provision

  3. India's Ranbaxy Laboratories posts loss in June quarter

    Headlines

    Tue, 29 Jul 2014

    MUMBAI, July 29 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd , which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

  4. UPDATE 2-India's Ranbaxy gets FDA approval for Novartis's Diovan generic

    Headlines

    Fri, 27 Jun 2014

    * Drug could add about $200 mln to Ranbaxy sales - analyst

  5. FDA approves Ranbaxy's generic version of Novartis's Diovan

    Headlines

    Thu, 26 Jun 2014

    June 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Ranbaxy Laboratories Ltd 's generic version of Novartis AG's blood pressure drug Diovan.

  6. INDIA PRESS-Clearances for Sun- Ranbaxy merger may be delayed-Business Standard

    Headlines

    Thu, 19 Jun 2014

    Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

  7. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

    Headlines

    Fri, 30 May 2014

    April bought Ranbaxy Laboratories for $4 billion from Japan’s Daiichi Sankyo . And French pharmaceutical ..... purchase of Ranbaxy Laboratories , the latter ..... Japan’s Daiichi Sankyo in 2008 bought a 64% stake in Ranbaxy for $4.2

  8. Sun's Unsustainably High Margins Ahead of Our Expectations

    Commentary

    Fri, 30 May 2014

    but we remain concerned about possible margin pressure from internal regulatory issues and the upcoming integration of Ranbaxy . Sun's U.S. business continued to lead the charge with 43% growth, as currency benefits and pricing power in many

  9. Sun Acquires Struggling Ranbaxy at Half the Price Daichii Paid for a Controlling Stake in 2008

    Commentary

    Mon, 7 Apr 2014

    acquire the ailing Indian pharmaceutical company Ranbaxy in an all-equity transaction. Each Ranbaxy shareholder will receive 0.8 shares of Sun ..... quality control and regulatory problems plaguing Ranbaxy 's recent performance. Assuming Sun can successfully

  10. India's Ranbaxy slumps, Sun Pharma surges on $3.2-billion acquisition

    Headlines

    Mon, 7 Apr 2014

    MUMBAI (Reuters) - Shares in India's Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after Sun Pharmaceutical Industries Ltd said it will buy the company in a $3.2 billion...

« Prev123Next »
Content Partners